# Deep Dive: What FDA’s QMSR Warning Letters Are Revealing

Page: https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing
Text version: https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing.md
Podcast: [Let's Talk Risk! Podcast](https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844)
Published: 2026-09-11T12:00:00+00:00
Episode link: https://naveenagarwalphd.substack.com/p/deep-dive-what-fdas-qmsr-warning-letters-are-revealing
Audio file: https://api.substack.com/feed/podcast/215055684/1af5f4af054c7af856736dd0d75c4561.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing
Duration seconds: 1273

## Resource

If you’re trying to manage risk in isolated silos, your quality management system is already obsolete. What happens when a supplier changes a device label without triggering design controls? When operators quietly rework nonconforming product? Or when serious post-market signals never make it back into the risk file? This Deep Dive examines recent FDA inspection and warning-letter examples through one common lens: the integration of risk management across the quality system. The cases illustrate how seemingly separate failures in supplier controls, manufacturing, complaints, nonconforming product, CAPA, and infrastructure can become connected risk-management failures under QMSR. Key highlights covered in the audio: * Why ISO 13485 Clause 7.1 is becoming so important — and how risk management increasingly connects multiple parts of the QMS. * Supplier changes can become risk-management events when labeling, intended use, or other product assumptions change without adequate escalation. * Undocumented shop-floor rework can hide risk signals , leaving management metrics looking healthy while process problems accumulate. * CAPA cannot work in isolation when environmental controls, process data, nonconformances, and risk analyses are disconnected. * A static risk file is no longer enough. Post-market experience, manufacturing changes, supplier issues, and emerging hazards must continually inform lifecycle risk management. The broader lesson is straightforward: QMSR is pushing companies away from managing compliance clause by clause and toward managing risk as an interconnected system. And that raises an important question for medical device organizations: When a new signal appears anywhere in your quality system, can it actually find its way back to the assumptions in your r…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.